Abstract
Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Current Signal Transduction Therapy
Title:Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Volume: 7 Issue: 3
Author(s): Eva-Maria Schottdorf
Affiliation:
Keywords: Resistance to radiotherapy, targeted therapy, combined therapy, squamous cell carcinoma of the head and neck (HNSCC), metalloproteinases, Polymorphisms, cytoskeleton, heterodimers, cetuximab
Abstract: Many patients suffering from head and neck squamous cell carcinoma (HNSCC) do not benefit from cetuximab added to radiotherapy. Some of the mechansisms leading to resistance to the combined treatment are already understood. However, they do not fully explain the resistance to multimodal therapy. In this review, potential mechanisms of resistance to therapy will be addressed, starting from the outside of the cells looking at the potential role the ECM may play, then continuing with EGF receptor alterations, which may contribute to resistance to therapy with antibodies. The role of FcγRIIIa receptor polymorphism in antibody-dependent cell-mediated cytotoxicity (ADCC), which may be a mechanism of anticancer activity of cetuximab will be discussed, as well as the resistance to radiotherapy and receptor blocking therapy mediated by the insulin-like growth factor receptor I (IGF-1R). Inside the cell, proteins expressed in radioresistant cells will be highlighted before turning the attention to the impact epithelial mesenchymal transition (EMT) may have on increased resistance to different treatment modalities. The last section of this review aims to outline potential treatment approaches, which, in the future, may help improve treatment response.
Export Options
About this article
Cite this article as:
Schottdorf Eva-Maria, Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481574
DOI https://dx.doi.org/10.2174/157436212802481574 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Hydroxamic Acids, Recent Breakthroughs in Stereoselective Synthesis and Biological Evaluations
Current Organic Synthesis Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry The Place of the Bioisosteric Sila-Substitution in Drug Design
Drug Design Reviews - Online (Discontinued) Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design NF-κB1 Intronic Region Polymorphisms as Risk Factor for Head and Neck Cancer in HPV-Infected Population from Pakistan
Current Molecular Medicine Impact of DNA Vector Topology on Non-Viral Gene Therapeutic Safety and Efficacy
Current Gene Therapy Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging N-arylmethylideneaminophthalimide: Design, Synthesis and Evaluation as Analgesic and Anti-inflammatory Agents
Mini-Reviews in Medicinal Chemistry Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Difference Gel Electrophoresis: Application in Quantitative Proteomics Research
Current Proteomics Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Anticancer Activity and In Silico ADMET Properties of 2,4,5-Trisubstitutedthiazole Derivatives
Current Drug Metabolism Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Induction of Apoptosis and Sensitization of Head and Neck Squamous Carcinoma Cells to Cisplatin by Targeting Survivin Gene Expression
Current Gene Therapy The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design